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Atovaquone is a new anti-malarial agent that specifi-
cally targets the cytochrome bc1 complex and inhibits
parasite respiration. A growing number of failures of this
drug in the treatment of malaria have been genetically
linked to point mutations in the mitochondrial cyto-
chrome b gene. To better understand the molecular basis
of atovaquone resistance in malaria, we introduced five of
these mutations, including the most prevalent variant
found in Plasmodium falciparum (Y268S), into the cyto-
chrome b gene of the budding yeast Saccharomyces cer-
evisiae and thus obtained cytochrome bc1 complexes re-
sistant to inhibition by atovaquone. By modeling the
variations in cytochrome b structure and atovaquone
binding with the mutated bc1 complexes, we obtained the
first quantitative explanation for the molecular basis of
atovaquone resistance in malaria parasites.
Up to one-half billion people in the world suffer from malaria
with various degrees of severity. The disease kills more than
2.7 million people a year, most of them children under 5 years
old in sub-Saharan Africa (1). Over the past three decades, the
parasite that causes malaria, Plasmodium falciparum, has
developed resistance to almost every commonly available anti-
malarial drug, including chloroquine, pyrimethamine, cy-
cloguanil, and sulfadoxine. Because some of these drugs are
now almost useless in many parts of the world, the rapid
spread of resistant parasites is a serious global health problem
in endemic countries.
In the 1990s, the urgent need for new anti-malarial drugs for
treatment and chemoprophylaxis led to the development of
atovaquone (2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hy-
droxy-1,4-hydroxynaphthoquinone). This recently introduced
anti-malarial compound, which has broad spectrum activity
against apicomplexan parasites (2–4), also prevents and clears
Pneumocystis pneumonia (5). Atovaquone is a potent and spe-
cific inhibitor of the cytochrome bc1 complex (EC 1.10.2.2) (6),
an essential respiratory enzyme present in the inner mitochon-
drial membrane. This drug was approved by the FDA in 1995
and is now distributed as a synergic combination with progua-
nil hydrochloride under the trade name of Malarone®. Despite
minimal side effects and high activity against malaria, the cost
of Malarone® treatment has, until now, restricted its use to
western non-immune adult and children (7) travelers and some
European military personnel (8).
Unfortunately, there is growing evidence that malarial par-
asites may quickly develop drug resistance by mutation of
amino acid residues located in or near the atovaquone-binding
site on cytochrome b (9–11). Within just a few years after its
introduction, the mitochondrial DNA sequences of isolates of
P. falciparum associated with Malarone® treatment failures
exhibit the same Y268S (malaria numbering) mutation of the
cytochrome b gene of the parasite. Because these isolates were
obtained from infected patients returning from Thailand (12),
Ivory Coast (13), Mali (14), Cameroon (15), and Kenya (16),
growing concern about the spread and the high frequency of
this mutation led to the design of PCR-based screening proce-
dures in Europe for quick detection in case of Malarone® treat-
ment failure (14, 17, 18).
Because the yeast bc1 complex is also inhibited by atova-
quone (6), we previously developed Saccharomyces cerevisiae as
a model to study cytochrome b mutations conferring atova-
quone resistance in Pneumocystis (19, 20). In the present study
we transferred several mutations associated with atovaquone
resistance in Plasmodium yoelii (9) and P. falciparum (10,
12–16) into the yeast cytochrome b gene. This allowed us to
biochemically confirm the linkage of atovaquone resistance to
the cytochrome b mutations and to explain at the molecular
level the mechanism by which malaria parasites counter the
therapeutic cytotoxicity of this new drug.
EXPERIMENTAL PROCEDURES
Materials—Yeast extract and peptone were from Difco. Nitrogen
base without amino acids but with ammonium sulfate was from U. S.
Biological. Dodecylmaltoside was obtained from Roche Applied Science.
DEAE-Biogel A was obtained from Bio-Rad. Decyl ubiquinone, diiso-
propylfluorophosphate, and dithionite were purchased from Sigma.
Stigmatellin was purchased from Fluka Biochemica. Atovaquone was a
gift from GlaxoSmithKline.
Purification of Cytochrome bc1 Complexes—The cytochrome b muta-
tions were introduced into the mitochondrial cytochrome b gene by
biolistic transformation as described elsewhere (19). Wild-type and
mutated yeast strains were grown in yeast extract/peptone/dextrose
medium and harvested by centrifugation. Cytochrome bc1 complexes
were then isolated from mitochondria as described previously (21, 22).
Measurement of Oxygen Consumption and Ubiquinol-Cytochrome c
Reductase Activity—Rates of oxygen uptake by intact yeast cells were
measured at 25 °C with a Gilson oxygraph and a polarographic oxygen
electrode (Gilson Medical Electronics, Middleton, WI) as described pre-
viously (23). Cytochrome c reductase activities of the cytochrome bc1
complexes were assayed in 50 mM potassium phosphate, pH 7.0, 250 mM
sucrose, 0.2 mM EDTA, 1 mM NaN3, 2.5 mM KCN, 0.01% Tween 20, and
40 M cytochrome c at 23 °C. The cytochrome bc1 complex was diluted
to 2.5 nM in the assay buffer, and the reaction was started by adding
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2,3-dimethoxy-5-methyl 6-decyl-1,4-benzoquinol, an analogue of ubiqui-
nol. The reduction of cytochrome c was monitored in an Aminco DW-2a
spectrophotometer at 550 versus 539 nm in dual wavelength mode.
Data were collected and analyzed using an Online Instrument Systems
Inc. computer interface and software.
Molecular Modeling—Molecular modeling was carried out on a Sili-
con Graphics O2 work station using the commercially available Insight
II® software package (Accelrys Inc., San Diego, CA). The starting
structure was the energy-minimized atovaquone-bound yeast cyto-
chrome bc1 complex (6). Each cytochrome b mutation, Y279S, Y279C,
I269M, L282V, and F278I, was built separately into the atovaquone-
bound center P site using the lowest energy manual rotamer selected by
the Biopolymer® module.
For each structure, a flexible subset of adjacent residues within 2.0 Å
of the mutation was selected. A surrounding 9.5-Å shell of residues,
including atovaquone, was kept fixed. Residues beyond this shell were
excluded from calculations in the interest of speed. The atom-based
cut-off for non-bonding interactions was set at 9.5 Å, and the dielectric
constant was set at 2.0. The CFF91 force field, which uses a 6–9
Lennard-Jones potential to calculate van der Waals interactions, was
used for all modeling.
A five-step simulated annealing run, from 800 to 298 K, was per-
formed on each mutated structure using the Discover 3® module in
Insight II®. At each of the five temperatures, the Nosé temperature
control method was used for a simulation time of 10,000 fs/step, with a
0.5 fs/iteration time step. The final structure was minimized to a final
convergence of 0.001 using Cauchy’s steepest descent, conjugate gradi-
ent, and Newton methods consecutively. Five simulated annealing runs
were carried out for each mutant structure to obtain an average
final energy.
To estimate the energy cost of binding atovaquone, we calculated the
energy of each mutant structure with the bound atovaquone and com-
pared it with the energy of the wild-type enzyme with bound atova-
quone. To compare non-bonding interaction energies (van der Waals
and electrostatic) and internal conformation energies of mutant and
wild-type structures, a common subset (20), including atovaquone, the
residue His-181 on the iron-sulfur protein, cytochrome b residues
within 4.0 Å of the inhibitor, and cytochrome b residues within 4.0 Å of
cytochrome b residue Glu-272, was used for all calculations.
RESULTS
Location of the Cytochrome b Mutations Conferring Atova-
quone Resistance to Plasmodium—The molecular target of
atovaquone is now known to be the ubiquinol oxidation pocket
at the center P site of the cytochrome bc1 complex (6). An
energy-minimized structure of atovaquone in the ubiquinol
oxidation pocket obtained by molecular modeling indicated
that the hydroxyl group of the hydroxy-naphthoquinone bound
via a hydrogen bond to the nitrogen of His-181 of the Rieske
iron-sulfur protein. This hydrogen bonding accounts for the
effects of atovaquone on the midpoint potential of the Rieske
protein (6) and mimics the hydrogen bond between undecyl
hydroxy benzoxythiazol and the Rieske protein in the crystal
structure of the undecyl hydroxy benzoxythiazol-bound bc1
complex (24). On the opposite side of the ring system, the
carbonyl group at position 4 of the quinone ring of atovaquone
formed a water-mediated hydrogen bond with Glu-272 of cyto-
chrome b. The remainder of the molecular interactions between
atovaquone and cytochrome b were essentially hydrophobic
with a network of aromatic and aliphatic side chains surround-
ing the inhibitor. This binding pattern is similar to the one
recently found in the crystal structure of the yeast bc1 complex
with undecyl hydroxy benzoxythiazol, a hydroxyquinone,
bound to the ubiquinol oxidation pocket (24).
Because there is a high degree of sequence identity (about
68%) between S. cerevisiae and Plasmodium cytochrome b
within the atovaquone-binding pocket (Fig. 1), we chose the
yeast for studying how mutations can affect the drug efficacy.
All atovaquone-resistant mutations in the cytochrome b se-
quence found in Plasmodium were localized around this bind-
ing site (9–14, 25). Five of these mutations associated with
resistance in P. yoelii (9) and P. falciparum (10–16) (Fig. 1)
were transferred into the S. cerevisiae cytochrome b gene by the
biolistic method (19).
The modeled structure of the yeast ubiquinol oxidation
pocket at the center P site with bound atovaquone and the
location of the amino acids residues affected in the atovaquone-
resistant cytochrome b mutants are shown in Fig. 2. These five
mutations are I258M, F267I, Y268C, Y268S, and L271V in
Plasmodium numbering, equivalent to I269M, F278I, Y279C,
Y279S, and L282V in the yeast numbering system (we will use
S. cerevisiae numbering of cytochrome b hereafter). Except for
I269M, which is located in the EF loop, all of the mutations
affect residues of the EF helix of cytochrome b.
Loss of Fitness Associated with the Cytochrome b Muta-
tions—Growth of the five mutated strains was monitored in a
non-fermentable medium to study the impact of the mutations
on the respiration of the yeast cells. The growth curves (Fig.
3A) reveal that, in contrast to a doubling time of 6 ( 0.5) h
observed for the wild-type strain and also for the I269M and
F278I mutants, the Y279C mutated strain had a doubling time
FIG. 1. Sequence alignment of the cytochrome b proteins of
S. cerevisiae and P. falciparum in the conserved regions includ-
ing residues 127–155 and 251–286 around the ubiquinol oxida-
tion pocket at the center P site. The alignment was constructed
using ClustalW and yeast numbering. The arrows show the positions of
the mutated residues in Plasmodium.
FIG. 2. View of the atovaquone-binding pocket of the yeast
cytochrome bc1 complex showing the location of mutations con-
ferring resistance to atovaquone in Plasmodium. Cytochrome b is
shown in cyan, and a portion of the Rieske iron-sulfur protein is in gold.
The iron-sulfur cluster is at the top right, with iron and sulfur atoms
colored purple and yellow, respectively. The carbon atoms in atova-
quone (ATV) are green, oxygen atoms are red, and hydrogen atoms are
white. The mutated residues are purple.
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of 9 ( 0.5) h. In addition, both the Y279S and L282V mutants
show even more severe growth defects, with doubling times of
13 ( 0.5) h.
Measurements of oxygen consumption of the yeast cells in
mid-log growth phase (Fig. 3B) confirmed a decrease of 60%
of the respiratory function for the Y279C, Y279S, and L282V
mutated strains. To further investigate this effect, the cyto-
chrome bc1 complex was purified from the mitochondria of each
strain to assess the kinetic parameters of the enzymes (Table
I). Again, the bc1 complexes from the three mutants Y279C,
Y279S, and L282V that showed significant defects in growth
rates and oxygen consumption also showed activity losses of
90% compared with the wild-type strain. These activities
were too low to permit accurate determination of Km and Vm
TABLE I
Kinetic parameters of purified cytochrome bc1 complexes from
wild-type and atovaquone-resistant yeast mutants
Yeast strains kcat KM
s1 M






a ND, not determined.
FIG. 4. Relative efficacy of inhibition of wild-type and mutated
bc1 complexes by atovaquone. Ubiquinol-cytochrome c reductase
activities of purified bc1 complexes were measured in the presence of
increasing concentrations of atovaquone. Activities are expressed as a
percentage of the activity of each bc1 complex in the absence of inhibitor
and are indicated as follows: , wild-type; f, Y279C; ‚, Y279S; Œ,
I269M; , F278I; and ●, L282V.
FIG. 3. Fitness of mutated yeast
strains. A, growth curves of wild-type
and mutated S. cerevisiae strains in non-
fermentable medium. Culture densities
are expressed in optical density at 600 nm
(OD600). The strains are wild type (),
F278I (●), I269M (Œ), Y279C (f), Y279S
(), and L282V () mutants. B, rates of
oxygen consumption by wild-type (WT)
and mutant S. cerevisiae strains. Oxygen
uptake rates are expressed in nanoatoms
of oxygen/107 yeast cells/min.
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values. The activity of the bc1 complex from the I269M mutant
was also low, although the growth rates and rates of oxygen
consumption by this yeast mutant were similar to and only
slightly less than those of the wild-type strain. This suggested
that the bc1 complex from the I269M mutant suffered some loss
of activity during isolation.
Western blots indicated no loss of iron-sulfur protein, and
optical spectra indicated no assembly defects in cytochromes b
or c1 that could account for these decreases of respiratory
function. Thus the results clearly suggest that these three
cytochrome b mutations associated with atovaquone resistance
in Plasmodium impair the ubiquinol-binding properties of the
yeast bc1 complex. Possible implications of this effect for the
growth of the parasite are discussed below.
Effect of Cytochrome b Mutations on Inhibition of the bc1
Cytochrome Complex by Atovaquone—Ubiquinol-cytochrome c
reductase activities of the purified bc1 complexes from the
wild-type and mutated yeast strains were measured in the
presence of increasing concentrations of atovaquone to test
whether sensitivity of the enzymes to the drug was altered by
the cytochrome b mutations. We have shown previously that
the bc1 complex of wild-type yeast is sensitive to atovaquone
with an inhibitor concentration of 25 nM required for 50%
inhibition of the activity of the purified enzyme (6). As shown in
Fig. 4, all of the cytochrome b mutations that confer atova-
quone resistance to the Plasmodium also altered the IC50 for
inhibition of the yeast bc1 complex and by various amounts.
The I269M and F278I mutations had the smallest effect, but
FIG. 5. Molecular modeling of atovaquone-resistant mutations of the bc1 complex from Plasmodium in S. cerevisiae. A–C, mutations
I269M, F278I, and L282V. For clarity, only atovaquone (green), wild-type residues (white), mutated residues (yellow), important aromatic
interacting residues (cyan), His-181 from the iron-sulfur protein (orange), and the affected residues Tyr-279 and Arg-283 are shown. D, views of
atovaquone binding in the bc1 complexes of wild-type yeast (D1) and the Y279S or Y279C mutants (D2). The figure was generated using GRASP
software. The chlorine on atovaquone is yellow, oxygens are red, and hydrogens are white. The yellow surface corresponds to the Rieske iron-sulfur
protein. The white surfaces were generated by hydrophobic and aromatic residues of the cytochrome b, and the red surfaces were generated by
hydrophilic and nucleophilic side chains.
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even these conferred a 5–10-fold increase in resistance, with
IC50 values between 150–250 nM. The Y279C, Y279S, and
L282V were the three cytochrome b mutations showing the
highest level of resistance to the atovaquone, with IC50 values
between 1 and 2 M. This corresponded to a 40–80-fold in-
crease over the concentration required to inhibit the
wild-type enzyme.
Structural Changes in Cytochrome b Caused by Mutations
Conferring Resistance to Atovaquone—The five cytochrome b
mutations responsible for atovaquone resistance in Plasmo-
dium were built into the previously modeled atovaquone-bound
ubiquinol oxidation pocket at the center P site of the yeast bc1
complex (6), and the structural changes resulting from the
mutations were modeled in silico. The isoleucine at position
269, located in a hydrophobic region of the binding pocket,
interacted directly with the naphthoquinone ring of atova-
quone. Modeling of the I269M mutation (Fig. 5A) showed a
decrease of the volume available in this hydrophobic pocket,
which interfered with binding of the inhibitor.
The phenylalanine at position 278 interacted directly with
the chlorophenyl substituent of atovaquone. Examination of
this region revealed the presence of an aromatic cluster com-
posed of Phe-121, Phe-278, Tyr-359 and the chlorophenyl group
of the atovaquone (Fig. 5B). The F278I mutation removed the
central aromatic element of this cluster, destabilized this area
of the pocket, and thus interfered with binding of the drug.
Tyrosine 279 is also contained in a stable aromatic cluster
composed of His-181 of the Rieske protein and the naphthoqui-
none group of the ligand. The modeling results in Fig. 5D
clearly show how the Y279C or Y279S mutations, which re-
place an aromatic group by strong nucleophilic side chains,
decreased the hydrophobic interactions between the binding
pocket and the atovaquone.
In the L282V mutant, two changes taking place simulta-
neously explain the decrease of atovaquone binding as shown
in Fig. 5C. First, Leu-282 interacted slightly with His-181 of
the Rieske protein subunit, and the L282V mutation modified
this interaction and influenced the degree of freedom of His-
181. Secondly, the reduction in size of the aliphatic side chain
created an empty space that the modeling compensated for by
adjusting the backbone geometry of residues 280–285. Exam-
ination of this region showed that this adjustment suppressed
a hydrogen bond between Arg-283 and Tyr-279 (Fig. 5C), which
caused a change in the orientation of Tyr-279 toward the bind-
ing pocket. Consequently, displacement of the Tyr-279 residue
caused an atovaquone-binding defect similar to the ones ob-
served for the Tyr-279 mutants and contributed to the effect of
the His-181 positioning.
Calculation of Changes in Atovaquone-binding Energy Re-
sulting from Mutations in Cytochrome b—The energy required
for binding atovaquone was calculated with each of the mod-
eled structures. The calculated changes in binding energy were
then compared with the experimentally measured changes in
IC50 values. The changes in atovaquone-binding energy with
the bc1 complexes from the mutants relative to the binding
energy obtained for the wild-type enzyme and the changes in
IC50 values for the mutant enzymes compared with the wild-
type enzyme are shown in Fig. 6. The relative increase in
calculated binding energy correlated well with the relative
increase in IC50 values for the bc1 complexes for each mutation,
with the exception of L282V. This mutation, which displayed
the largest change among the IC50 values, did not yield a
comparably large increase in calculated binding energy. Possi-
ble reasons for this difference are discussed below.
DISCUSSION
Only a decade after the introduction of the anti-malarial
drug atovaquone, new strains of P. falciparum that are resist-
ant to the therapy have emerged worldwide. In this work, we
used the budding yeast S. cerevisiae as a surrogate to recapit-
ulate and understand the molecular basis of the atovaquone
resistance found in the malaria parasites. It is well known that
atovaquone suppresses the respiratory function of the parasite
by inhibiting the cytochrome bc1 complex (26). The drug is also
a potent inhibitor of the yeast bc1 complex (6), and the binding
sites of the enzyme in the two microorganisms show a high
degree of identity.
We have previously elucidated the mechanism of atovaquone
inhibition of the bc1 complex and developed a molecular model
of atovaquone interaction with the ubiquinol oxidation pocket
of the enzyme that accounts for the effects of the drug on the
isolated enzyme (6). The strong and highly specific binding
between the bc1 complex and atovaquone results from a com-
bination of aromatic interactions and several hydrogen bonds,
some of which mimic the binding determinants of the natural
substrate, ubiquinol. Atovaquone is thus a competitive inhibi-
tor of the enzyme.
Most of the atovaquone-resistant malaria strains contain
point mutations in the mitochondria-encoded cytochrome b
gene. We were able to transfer these mutations into the yeast
mitochondrial genome using a biolistic transformation proce-
dure. Some of the resulting mutants were unable to grow on
non-fermentable carbon sources, and thus it was not possible to
demonstrate atovaquone resistance in vivo. However, the bc1
complexes purified from the mutated strains exhibited large
decreases in sensitivity toward atovaquone. We were thus able
to biochemically confer the genetic evidence that linked these
mutations to atovaquone resistance.
A previous study done on Plasmodium (9) demonstrates that
these mutations can be ranked by the effects of atovaquone on
the collapse of the mitochondrial membrane potential of the
parasite. This ranking resulted in moderate atovaquone resist-
ance for I269M and F278I and greater resistance for Y279C
and L282V. Notably, these mutations transferred into S. cer-
evisiae produced the same ranking order, demonstrating that
the yeast bc1 complex is a valuable model for atovaquone
resistance.
In a recent study of mutations conferring atovaquone resist-
ance in pathogenic Pneumocystis fungi, we show that one-half
of the mutations are distal from the drug-binding pocket, and
these are able to remotely modify the drug-binding properties
of the bc1 complex (20). Interestingly, all of the Plasmodium
FIG. 6. Measured changes in atovaquone inhibition and mod-
eled changes in atovaquone binding with atovaquone-resistant
cytochrome bc1 complexes. The light gray bars indicate the change
in IC50 for inhibition of the bc1 complexes by atovaquone compared with
inhibition of the enzyme from wild-type yeast. The dark bars show the
calculated change in binding energy for atovaquone with each of the
mutated bc1 complexes versus that with the wild-type enzyme.
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mutations that we duplicated in yeast in the present study
affected residues located in the binding pocket and interacting
directly with the atovaquone. The molecular modeling simula-
tions were able to describe the effects of each point mutation on
the geometry of the atovaquone-binding pocket at the molecu-
lar level.
The molecular modeling revealed that the I269M mutation,
which includes the insertion of a bulkier residue, is a typical
example of resistance acquired by increasing steric constraints
on the inhibitor. Several atovaquone-resistant mutations
(I147V, L150F, and L275F) found in Pneumocystis have been
shown to have analogous steric effects (20).
The three mutations F278I, Y279S, and Y279C removed an
aromatic residue localized near the atovaquone and suppressed
important interactions between the drug and the binding
pocket. Likewise, molecular modeling of the L282V mutation
showed that the mutation caused the rotation of Tyr-279 and,
consequently, a variation of aromatic interaction with the
atovaquone. Tight binding to the same locus using a very
similar aromatic network has been described for the fungicide
famoxadone, another inhibitor of the bc1 complex (27). Inter-
estingly, Plasmodium, Saccharomyces, and Pneumocystis,
which have atovaquone-sensitive bc1 complexes, all have a
phenylalanine in position 278 of cytochrome b, whereas the
bovine and human cytochrome bc1 complexes, which are rela-
tively insensitive to atovaquone, have an alanine at the equiv-
alent cytochrome b position. The 278 locus thus appears to be
important for the differential efficacy of the drug, similar to the
position 275 (6).
The importance of Tyr-279 in cytochrome b for bc1 activity is
supported by its conservation among species. It has been pos-
tulated that the aromatic side chain of this tyrosine partici-
pates in the positioning of ubiquinol, the natural substrate of
the enzyme (24). In Rhodobacter sphaeroides (28), mutation of
the homologous tyrosine has no effect on the activity when
replaced by phenylalanine, a small effect (3-fold decrease)
when replaced by leucine, and a dramatic effect (20-fold de-
crease) when replaced with a glycine. In yeast (29), mutation of
the same tyrosine into alanine causes an 5-fold decrease in
bc1 complex activity. Therefore, the 279 position appears to
require an aromatic side chain, or at least a large hydrophobic
residue, to maintain a functional bc1 complex. Furthermore,
when this position is occupied by a nucleophilic residue such as
cysteine (Y279C) or serine (Y279S), the activity is severely
compromised. The sulfur atom of the cysteine being less elec-
tronegative than the oxygen atom of the serine would account
for the differences between the two mutations. The Y279C
mutation has also been observed clinically in a human bc1
complex, in which case the mutation was associated with se-
vere exercise intolerance, deafness, and mental retardation
(29, 30).
The comparison of experimentally measured changes in IC50
values for inhibition by atovaquone and theoretically calcu-
lated changes in binding energies provides a useful check on
the validity of the molecular modeling. With one exception,
there was generally good agreement between these two param-
eters. The one outlier, the L282V mutation, exhibited a rela-
tively greater change in IC50 than would be predicted from the
calculated change in binding energy. This may reflect the fact
that IC50 is a free energy (G) term, which includes an entropic
parameter, whereas the calculated binding energy is solely
enthalpic (H). Alternatively, the divergence for this mutation
may be because of a failure of the molecular mechanics algo-
rithms to accurately evaluate the energy variation associated
with the rotation of an element of a stable aromatic cluster.
It is extremely challenging and costly to establish malaria
cultures from patient blood (and probably impossible to do so in
third world country facilities), so it is difficult to prove that a
specific novel mutation of the cytochrome b gene is responsible
for a specific patient failing treatment with Malarone®. The
yeast model makes it possible to demonstrate and quantify
which mutations confer atovaquone resistance and which are
just coincidental allele variations.
Two of the mutations, Y279S and L282V, severely impaired
the ability of the yeast strains to grow on a non-fermentable
carbon source. It has been observed that some atovaquone-
resistant mutations cause changes in cytochrome b, leading to
a loss of fitness in the malaria parasite (31). This is frequently
observed in mutations that confer drug resistance to microor-
ganisms by alteration of structurally important regions of the
target molecules (32, 33). In the case of atovaquone, this loss of
fitness results from mutations close to the active site that
reduce the binding of the ubiquinol substrate by the enzyme.
There is no report that the widespread Y279S mutation causes
a loss of fitness in P. falciparum, but our yeast model strongly
predicts it. The implication of this prediction is important for
the future development and use of the drug Malarone®, be-
cause it suggests that the geographic spreading of a single locus
change such as the Y279S mutation will be stopped by the
removal of the drug. As the resistant strain has to compete
against a more fit, wild-type parasite, the reversal of atova-
quone resistance will happen spontaneously.
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